Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Syzygymed Inc. is currently managing 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are spread across 5 distinct examiners and 4 distinct art units, which represents a high degree of distribution for a portfolio of this size. The involvement of 4 art units suggests that the company's technology spans specialized sub-fields within the biotechnology sector, requiring technical expertise from different sections of the patent office.
The busiest examiner, HOPKINS, SAMANTHA LAKE, is responsible for 1 busiest examiner pending action. Because each of the 5 pending actions is assigned to a different examiner, the company faces 5 unique sets of examiner behaviors and expectations. This diversity in the prosecution team means that no examiner has a dominant influence over the portfolio's immediate outcomes. Practitioners must coordinate across the 4 art units to ensure consistent messaging, as the 5 pending actions are being evaluated by 5 distinct examiners. This distributed workload requires a comprehensive strategy to manage the different examiner expectations within the Biotechnology & Pharmaceuticals area.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| §102 only | 1 (20%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPKINS, SAMANTHA LAKE | 1 | 60.4% | +62.3% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.6% |
| MCCORMICK, CATHERINE LYNN | 1 | 50.0% | +42.5% |
| SULLIVAN, DENNIS JOHN | 1 | 57.3% | +49.1% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638607 | COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION | SULLIVAN, DENNIS JOHN | 56d overdue |
| 18036698 | METHODS AND COMPOSITIONS RELATING TO GENETICALLY ENGINEERED CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | HOPKINS, SAMANTHA LAKE | — |
| 18033461 | COMPOSITIONS AND METHODS FOR TREATING HEMATOPOIETIC MALIGNANCY | HUYNH, PHUONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17638607 | COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION | SULLIVAN, DENNIS JOHN | 56d overdue |
| 17638610 | COMPOSITIONS AND METHODS FOR CD123 MODIFICATION | LIPPOLIS, ALEXANDRA ROSE | 69d |
| 18036698 | METHODS AND COMPOSITIONS RELATING TO GENETICALLY ENGINEERED CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | HOPKINS, SAMANTHA LAKE | — |
| 18033461 | COMPOSITIONS AND METHODS FOR TREATING HEMATOPOIETIC MALIGNANCY | HUYNH, PHUONG N | — |
| 18023561 | COMPOSITIONS AND METHODS FOR CD123 MODIFICATION | MCCORMICK, CATHERINE LYNN | — |
| Art Unit | Apps |
|---|---|
| 1641 | 2 |
| 1638 | 1 |
| 1642 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036698 | METHODS AND COMPOSITIONS RELATING TO GENETICALLY ENGINEERED CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | HOPKINS, SAMANTHA LAKE | 1641 | §102§112Other | Non-Final OA | — | Pending | May 12, 2023 |
| 18033461 | COMPOSITIONS AND METHODS FOR TREATING HEMATOPOIETIC MALIGNANCY | HUYNH, PHUONG N | 1641 | §102§103§112 | Non-Final OA | — | Pending | Apr 24, 2023 |
| 18023561 | COMPOSITIONS AND METHODS FOR CD123 MODIFICATION | MCCORMICK, CATHERINE LYNN | 1638 | §102 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 17638607 | COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION | SULLIVAN, DENNIS JOHN | 1642 | §103§112 | Non-Final OA | 56d overdue | Pending | Feb 25, 2022 |
| 17638610 | COMPOSITIONS AND METHODS FOR CD123 MODIFICATION | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103 | Final Rejection | 69d | Pending | Feb 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial